Latest filings (excl ownership)
15-12B
Securities registration termination
26 Sep 13
EFFECT
Notice of effectiveness
9 Sep 13
POS AM
Prospectus update (post-effective amendment)
6 Sep 13
S-8 POS
Registration of securities for employees (post-effective amendment)
6 Sep 13
S-8 POS
Registration of securities for employees (post-effective amendment)
6 Sep 13
25-NSE
Exchange delisting
30 Aug 13
8-K
Completion of Acquisition or Disposition of Assets
30 Aug 13
10-Q
2013 Q2
Quarterly report
9 Aug 13
DEFM14A
Proxy related to merger
24 Jul 13
PRER14A
Preliminary revised proxy
16 Jul 13
PRER14A
Preliminary revised proxy
10 Jul 13
425
Business combination disclosure
3 Jul 13
8-K
PROLOR BIOTECH TO PRESENT POSITIVE RESULTS FROM PRECLINICAL STUDIESOf
3 Jul 13
PREM14A
Preliminary proxy related to merger
28 Jun 13
8-K
Regulation FD Disclosure
17 Jun 13
S-8
Registration of securities for employees
12 Jun 13
8-K
Departure of Directors or Certain Officers
7 Jun 13
8-K
PROLOR BIOTECH initiates PIVOTAL phase III trial of ITS Longer-Acting Version of human growth hormone
4 Jun 13
DEFA14A
Additional proxy soliciting materials
4 Jun 13
10-Q
2013 Q1
Quarterly report
10 May 13
ARS
2012 FY
Annual report to shareholders
3 May 13
8-K
Entry into a Material Definitive Agreement
29 Apr 13
DEFA14A
Additional proxy soliciting materials
29 Apr 13
DEF 14A
Definitive proxy
25 Apr 13
DEFA14A
Additional proxy soliciting materials
25 Apr 13
425
Business combination disclosure
24 Apr 13
8-K
Opko Health to Acquire Prolor Biotech
24 Apr 13
DEFA14A
Additional proxy soliciting materials
24 Apr 13
10-K
2012 FY
Annual report
15 Mar 13
8-K
Departure of Directors or Certain Officers
8 Feb 13
8-K
PROLOR BIOTECH TO PRESENT NEW PRECLINICAL DATA ON ITS LONG-ACTING CLOTTING FACTOR Vlla AT LEADING EUROPEAN SCIENTIFIC CONFERENCE
6 Feb 13
8-K
Regulation FD Disclosure
12 Dec 12
8-K
PROLOR BIOTECH TO PRESENT PRECLINICAL DATA ON ITS LONG-ACTING CLOTTING FACTOR Vlla AT 2012 ASH ANNUAL MEETING
7 Dec 12
10-Q
2012 Q3
Quarterly report
8 Nov 12
8-K
Departure of Directors or Certain Officers
7 Nov 12
10-Q
2012 Q2
Quarterly report
9 Aug 12
8-K
Submission of Matters to a Vote of Security Holders
7 Jun 12
8-K
PROLOR BIOTECHAnnounces PROPOSED Public Offering of Common Stock
14 May 12
424B5
Prospectus supplement for primary offering
11 May 12
424B5
Prospectus supplement for primary offering
11 May 12